ProPhase Labs Reports Deeper FY25 Loss of $1.74/Share, Revenue Down 36%; 10-K Reveals Going Concern Warning
PRPH sits 70% above its 52-week low of $0.068.
Summary
ProPhase Labs reported a fiscal 2025 loss of $1.74 per share, which is worse than the $1.5 loss per share previously indicated by Dow Jones. Revenue also fell sharply by 35.8% year-over-year to $4.35 million, driven by reduced consumer product sales and the end of diagnostic testing. The underlying 10-K filing, which this news summarizes, further reveals a going concern warning and that the company's diagnostic subsidiaries entered Chapter 11 bankruptcy in September 2025. These results and disclosures highlight significant financial distress and operational challenges for the micro-cap company.
At the time of this announcement, PRPH was trading at $0.12 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.1M. The 52-week trading range was $0.07 to $66.59. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.